Umbilical cord blood-derived mesenchymal stem cells in treating a critically ill COVID-19 patient.
J Infect Dev Ctries
; 14(10): 1138-1145, 2020 Oct 31.
Article
in English
| MEDLINE | ID: covidwho-918914
ABSTRACT
INTRODUCTION:
The coronavirus disease 2019 (COVID-19) pandemic is spreading rapidly. Critically ill cases of COVID-19 can rapidly progress to acute respiratory distress syndrome and multiple organ failures. However, no effective drugs have been available till now, leading to more than 300,000 deaths up to 29 April 2020. Here, we present a critically ill case utilizing umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs). CASE PRESENTATION A 72-year-old man was admitted, with the diagnosis of COVID-19, ARDS, type-2 diabetes, diabetic nephropathy, renal insufficiency, and hypertension. His clinical condition continually developed to be life-threatening even receiving various treatment options including antiviral therapy and extracorporeal membrane oxygenation. Between 28 February and 8 March 2020, the patient was given 5-time intravenous infusions of UCB-MSCs. His hematological and biochemical indexes, including lymphocytes and renal function improved. Pulmonary static compliance increased significantly and PaO2/FiO2 ratio maintained stable. On March 10, he received lung transplantation.CONCLUSIONS:
Our current findings suggested that UCB-MSCs therapy may show some positive effect in treating critical COVID-19 to some extent, for its delaying deterioration of the disease and efficacy in respiratory and renal function, though limited.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Mesenchymal Stem Cell Transplantation
/
Fetal Blood
Type of study:
Case report
/
Prognostic study
Limits:
Aged
/
Humans
/
Male
Language:
English
Journal:
J Infect Dev Ctries
Journal subject:
Communicable Diseases
Year:
2020
Document Type:
Article
Affiliation country:
Jidc.13081
Similar
MEDLINE
...
LILACS
LIS